ArticleFrontiers in endocrinology2026
Progesterone levels on hCG trigger day and neonatal outcomes in fresh embryo transfers: a retrospective threshold analysis of GnRH antagonist versus agonist long protocols.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Elevated progesterone levels on the day of human chorionic gonadotropin (hCG) trigger are known to adversely affect pregnancy outcomes in fresh embryo transfer (fET) cycles, but their impact on neonatal outcomes remains poorly understood. This study aimed to investigate the association between progesterone levels on hCG trigger day and neonatal outcomes, and to explore the progesterone threshold, so as to provide reference for clinical decision-making. Methods: This retrospective cohort study included 2, 201 patients who achieved singleton live births following fET between April 1, 2021 and December 31, 2024. All patients were ≤ 42 years of age and underwent either a GnRH antagonist protocol or an agonist long protocol. A multivariable regression analysis was performed to detect the relationship between progesterone level and neonatal outcomes. Smooth curve fitting and threshold effect analysis were used to evaluate the cutoff value of progesterone level. Results: In the overall population, higher progesterone levels were significantly associated with increased risks of preterm delivery (PTD) (adjusted OR: 1.89, 95% CI: 1.03 to 3.47, P = 0.0399) and low birthweight (LBW) (adjusted OR: 2.67, 95% CI: 1.14 to 6.24, P = 0.0231). These associations were observed only in the GnRH antagonist protocol, particularly with progesterone ≥ 1.0 ng/mL significantly elevating the risks of PTD (adjusted OR: 4.54, 95% CI: 2.16 to 9.56, P = 0.0021) and LBW (adjusted OR: 4.16, 95% CI: 1.15 to 15.07, P = 0.0378). Threshold analysis further identified progesterone > 0.90 ng/mL as the inflection point for PTD (adjusted OR: 6.60, 95% CI: 2.52 to 14.56, P = 0.0131) and progesterone > 0.98 ng/mL for LBW (adjusted OR: 7.50, 95% CI: 3.71 to 15.87, P = 0.0038) in antagonist cycles. No such associations were found in the GnRH agonist long protocol. Conclusions: Our findings suggest that in GnRH antagonist cycles, a serum progesterone level exceeding 0.90 ng/mL on hCG trigger day may serve as an independent predictor of an increased risk of PTD in singletons born after fET. These results highlight the need for enhanced perinatal surveillance in this population, and call for further validation in larger prospective multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.